Cotinga Pharmaceuticals (COTQF) versus The Competition Head to Head Review
Cotinga Pharmaceuticals (OTCMKTS: COTQF) is one of 493 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Cotinga Pharmaceuticals to similar businesses based on the strength of its valuation, profitability, analyst recommendations, institutional ownership, dividends, risk and earnings.
Insider and Institutional Ownership
47.5% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 15.8% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This is a summary of recent ratings and recommmendations for Cotinga Pharmaceuticals and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cotinga Pharmaceuticals Competitors||3026||9142||22121||633||2.58|
As a group, “Pharmaceutical preparations” companies have a potential upside of 38.35%. Given Cotinga Pharmaceuticals’ rivals higher probable upside, analysts plainly believe Cotinga Pharmaceuticals has less favorable growth aspects than its rivals.
Valuation & Earnings
This table compares Cotinga Pharmaceuticals and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Cotinga Pharmaceuticals||N/A||-$4.71 million||-1.96|
|Cotinga Pharmaceuticals Competitors||$2.01 billion||$135.76 million||-3.65|
Cotinga Pharmaceuticals’ rivals have higher revenue and earnings than Cotinga Pharmaceuticals. Cotinga Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Risk & Volatility
Cotinga Pharmaceuticals has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500. Comparatively, Cotinga Pharmaceuticals’ rivals have a beta of 1.09, indicating that their average share price is 9% more volatile than the S&P 500.
This table compares Cotinga Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cotinga Pharmaceuticals Competitors||-2,974.57%||-159.20%||-30.61%|
Cotinga Pharmaceuticals rivals beat Cotinga Pharmaceuticals on 7 of the 9 factors compared.
About Cotinga Pharmaceuticals
Cotinga Pharmaceuticals Inc., a biopharmaceutical company, develops therapies for the treatment of cancers. The company's lead compound is COTI-2, a clinical stage small molecule targeting p53 proteins, as well as is in the Phase I clinical trial for the treatment of gynecologic cancers, and head and neck squamous cell carcinoma. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. was founded in 1999 and is based in Boston, Massachusetts.
Receive News & Ratings for Cotinga Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cotinga Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.